Posted by Michael Wonder on 21 Jul 2017
CHMP recommends EU approval for Roche’s Tecentriq (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
21 July 2017 - Tecentriq as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer.
Roche today announced that the EU CHMP has adopted a positive opinion for Tecenriq (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer after they have been previously treated with chemotherapy. People with EGFR activating mutations or ALK positive tumour mutations should also have received targeted therapy before receiving Tecentriq. This positive recommendation is based on results from the large randomised Phase III OAK study and the randomised Phase II POPLAR study.
The CHMP has also adopted a positive opinion for the use of Tecentriq as a monotherapy for the treatment of adults with locally advanced or metastatic urothelial carcinoma who have been previously treated with a platinum based chemotherapy or who are considered ineligible for cisplatin chemotherapy. This positive opinion is based on results from the randomised Phase III IMvigor211 study and cohorts 1 and 2 from the single-arm Phase II IMvigor210 study.
